《大行報告》瑞信下調微創醫療(00853.HK)目標價至20.5元 評級「中性」
瑞信發表報告指,微創醫療(00853.HK)去年下半年收入按年增長10.6%,淨虧損按年進一步擴大28%。不過,管理層對復甦增長前景充滿信心,對2023財年收入指引為按年25至30%增長,並預計將通過顯著的成本控制來縮窄淨虧損。
報告指,根據公司對毛利率和營業費用的指引,2023財年的營運利潤率可提高約25個百分點,如果能夠實現,將是該行所見醫療保健公司中最大的營運利潤率改善幅度之一。維持「中性」評級,並將目標價由22元下調為20.5元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.